LY364947
Suppliers
Names
[ CAS No. ]:
396129-53-6
[ Name ]:
LY364947
[Synonym ]:
4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline
Quinoline, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
LY 364947
4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]quinoline
LY364947
LY-364947
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Boiling Point ]:
490.8±45.0 °C at 760 mmHg
[ Molecular Formula ]:
C17H12N4
[ Molecular Weight ]:
272.304
[ Flash Point ]:
268.7±15.1 °C
[ Exact Mass ]:
272.106201
[ PSA ]:
54.46000
[ LogP ]:
2.35
[ Appearance of Characters ]:
white to beige
[ Vapour Pressure ]:
0.0±1.2 mmHg at 25°C
[ Index of Refraction ]:
1.700
[ Storage condition ]:
Store at RT
[ Water Solubility ]:
DMSO: soluble2mg/mL, clear
MSDS
Safety Information
[ Symbol ]:
GHS06, GHS09
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H315-H319-H335-H400
[ Precautionary Statements ]:
P261-P273-P301 + P310-P305 + P351 + P338
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
[ Hazard Codes ]:
T,N
[ Risk Phrases ]:
25-36/37/38-50/53
[ Safety Phrases ]:
26-45-60-61
[ RIDADR ]:
UN 2811 6.1/PG 3
[ HS Code ]:
2933990090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2933990090
[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
J. Med. Chem. 46 , 3953-3956, (2003)
Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted ...
J. Med. Chem. 49 , 2138-2142, (2006)
Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed ...
Bioorg. Med. Chem. Lett. 13 , 4355-4359, (2003)
We describe the discovery, using shape-based virtual screening, of a potent, ATP site-directed inhibitor of the TbetaRI kinase, an important and novel drug target for fibrosis and cancer. The first de...